These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
798 related articles for article (PubMed ID: 30514385)
1. Oncolytic virus immunotherapy: future prospects for oncology. Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic viruses-immunotherapeutics on the rise. Keller BA; Bell JC J Mol Med (Berl); 2016 Sep; 94(9):979-91. PubMed ID: 27492706 [TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Oncolytic Viruses: A Systematic Review. Cook M; Chauhan A Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053757 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic Viruses: Therapeutics With an Identity Crisis. Breitbach CJ; Lichty BD; Bell JC EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991 [TBL] [Abstract][Full Text] [Related]
6. The viral approach to breast cancer immunotherapy. Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692 [TBL] [Abstract][Full Text] [Related]
7. Updates to the antitumor mechanism of oncolytic virus. Bai Y; Hui P; Du X; Su X Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824 [TBL] [Abstract][Full Text] [Related]
8. The role of oncolytic virus immunotherapies to subvert cancer immune evasion. Workenhe ST; Verschoor ML; Mossman KL Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic Immunotherapy for Treatment of Cancer. Tsun A; Miao XN; Wang CM; Yu DC Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460 [TBL] [Abstract][Full Text] [Related]
11. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Rojas JJ; Sampath P; Hou W; Thorne SH Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y Front Immunol; 2021; 12():721830. PubMed ID: 34675919 [TBL] [Abstract][Full Text] [Related]
13. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Rajani KR; Vile RG Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic virus therapy: A new era of cancer treatment at dawn. Fukuhara H; Ino Y; Todo T Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853 [TBL] [Abstract][Full Text] [Related]
15. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic HSV as a vector in cancer immunotherapy. Li H; Zhang X Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972 [TBL] [Abstract][Full Text] [Related]
18. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981 [TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517 [TBL] [Abstract][Full Text] [Related]